FDA Brief

Warning letters Drugs

FDA warning letter to

Happy Farm Botanicals, Inc.

High riskIssued Sep 1Posted Sep 8Center for Drug Evaluation and Research (CDER)

Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.

What happened

FDA inspected the company's drug manufacturing facility at 3708 West Street, Hyattsville, MD, from March 30 to April 2, 2026. Inspectors found no specific identity testing of incoming ingredients (including an active ingredient used in finished batches from March 2025 to September 2025, where only appearance and smell were checked), an inadequate stability program with failing viscosity results left uninvestigated, and a quality unit that had not validated manufacturing or cleaning processes. FDA also noted that the company had promised in its April 2024 response to finish process and cleaning validation by December 2024 but did not, and that the company's April 22, 2026 response to the inspection findings was inadequate.

What FDA found

  1. The company did not run at least one specific identity test on each ingredient before using it, testing some active ingredient only by appearance and smell.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The company did not properly qualify a supplier, and the supplier's requalification date had already lapsed.

    21 CFR 211.84(d)(2)
  3. The stability program was inadequate: accelerated studies had no controlled humidity, some timepoints were recorded as "Not Available," and failing viscosity results at accelerated and 12-month long-term timepoints were not investigated.

    21 CFR 211.166(a)
  4. Manufacturing processes for OTC drug products were never validated, and cleaning of shared (non-dedicated) equipment was never validated.

    21 CFR 211.100(a) and 21 CFR 211.67(b)(3)
  5. The quality unit did not do its job: it did not investigate recurring gasket seal failures on equipment or set proper content release limits for active ingredients in finished products.

    21 CFR 211.22, 211.67(a), 211.160(b)
  6. Violations cited in 2024 came back because the company did not carry out the process validation and cleaning validation it had committed to finish by December 2024.

What FDA wants

FDA tells the company to send a written response within 15 business days to CDER-OC-OMQ-Communications@fda.hhs.gov, identified by FEI 3011407349 and ATTN: Christopher Leach, covering an independent review of its material system, a stability program remediation plan, quality unit fixes, cleaning and process validation, and a risk assessment for distributed batches. The company must also say whether it has made or will resume making drugs, notify FDA before resuming, and engage a qualified consultant under 21 CFR 211.34 to do a six-system CGMP audit.

Who should pay attention

  • brands and retailers selling OTC drug products made by this contract manufacturer
  • companies that buy botanical ingredients or actives on the strength of a supplier's certificate of analysis alone
  • quality leaders at small OTC drug makers with lapsed supplier requalification or no process validation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk